BGI Genomics Co., Ltd. (300676.SZ)
CNY 49.18
(-0.06%)
CNY 49.18
(-0.06%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.93 Billion CNY | -20.43% |
| 2022 | 2.43 Billion CNY | 16.99% |
| 2021 | 2.08 Billion CNY | -6.63% |
| 2020 | 2.23 Billion CNY | 103.53% |
| 2019 | 1.09 Billion CNY | 20.32% |
| 2018 | 911 Million CNY | 28.58% |
| 2017 | 708.49 Million CNY | 5.26% |
| 2016 | 673.08 Million CNY | 44.07% |
| 2015 | 467.18 Million CNY | 2.13% |
| 2014 | 457.46 Million CNY | 25.2% |
| 2013 | 365.38 Million CNY | 43.93% |
| 2012 | 253.85 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 431.97 Million CNY | 7.41% |
| 2024 Q3 | 503.67 Million CNY | 25.47% |
| 2024 Q1 | 402.18 Million CNY | -26.88% |
| 2023 Q3 | 507.86 Million CNY | 10.94% |
| 2023 FY | 1.93 Billion CNY | -20.43% |
| 2023 Q1 | 423.56 Million CNY | -49.14% |
| 2023 Q2 | 457.79 Million CNY | 8.08% |
| 2023 Q4 | 550.02 Million CNY | 8.3% |
| 2022 FY | 2.43 Billion CNY | 16.99% |
| 2022 Q4 | 832.77 Million CNY | 41.69% |
| 2022 Q3 | 587.75 Million CNY | -1.05% |
| 2022 Q2 | 593.97 Million CNY | 40.57% |
| 2022 Q1 | 422.53 Million CNY | -37.07% |
| 2021 Q2 | 551.72 Million CNY | 52.51% |
| 2021 Q4 | 671.41 Million CNY | 34.77% |
| 2021 FY | 2.08 Billion CNY | -6.63% |
| 2021 Q3 | 498.19 Million CNY | -9.7% |
| 2021 Q1 | 361.75 Million CNY | -71.0% |
| 2020 FY | 2.23 Billion CNY | 103.53% |
| 2020 Q1 | 271.66 Million CNY | -17.38% |
| 2020 Q2 | 358.66 Million CNY | 32.02% |
| 2020 Q3 | 353.31 Million CNY | -1.49% |
| 2020 Q4 | 1.24 Billion CNY | 253.05% |
| 2019 Q4 | 328.8 Million CNY | 8.28% |
| 2019 FY | 1.09 Billion CNY | 20.32% |
| 2019 Q3 | 303.66 Million CNY | 23.48% |
| 2019 Q2 | 245.91 Million CNY | 12.93% |
| 2019 Q1 | 217.76 Million CNY | -30.97% |
| 2018 FY | 911 Million CNY | 28.58% |
| 2018 Q1 | 157.37 Million CNY | -36.36% |
| 2018 Q2 | 201.05 Million CNY | 27.75% |
| 2018 Q3 | 237.11 Million CNY | 17.94% |
| 2018 Q4 | 315.45 Million CNY | 33.04% |
| 2017 Q1 | 128.55 Million CNY | -40.0% |
| 2017 Q2 | 164.04 Million CNY | 27.61% |
| 2017 Q3 | 168.62 Million CNY | 2.79% |
| 2017 Q4 | 247.26 Million CNY | 46.64% |
| 2017 FY | 708.49 Million CNY | 5.26% |
| 2016 FY | 673.08 Million CNY | 44.07% |
| 2016 Q4 | 214.23 Million CNY | 9.22% |
| 2016 Q3 | 196.15 Million CNY | 16.8% |
| 2016 Q2 | 167.93 Million CNY | 77.2% |
| 2016 Q1 | 94.76 Million CNY | 0.0% |
| 2015 FY | 467.18 Million CNY | 2.13% |
| 2015 Q1 | 107.37 Million CNY | 0.0% |
| 2015 Q2 | 107.37 Million CNY | 0.0% |
| 2014 FY | 457.46 Million CNY | 25.2% |
| 2013 FY | 365.38 Million CNY | 43.93% |
| 2012 FY | 253.85 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 3.35 Billion CNY | 42.159% |
| Hangzhou Tigermed Consulting Co., Ltd. | 358.41 Million CNY | -441.062% |
| Dirui Industrial Co.,Ltd. | 387.16 Million CNY | -400.887% |
| Beijing Strong Biotechnologies, Inc. | 702.74 Million CNY | -175.955% |
| Medicalsystem Biotechnology Co., Ltd. | 562.06 Million CNY | -245.024% |
| Maccura Biotechnology Co.Ltd | 1.18 Billion CNY | -64.286% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.17 Billion CNY | -64.989% |
| Guangdong Hybribio Biotech Co.,Ltd. | 631.43 Million CNY | -207.118% |
| Amoy Diagnostics Co., Ltd. | 574.96 Million CNY | -237.282% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 479.96 Million CNY | -304.038% |